FMP
Ascendis Pharma A/S
ASND
NASDAQ
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
136.38 USD
-1.36 (-0.997%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Jan Moller Mikkelsen
sector
Healthcare
industry
Biotechnology
website
https://ascendispharma.comexchange
NASDAQ
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
CIK
0001612042
ISIN
US04351P1012
CUSIP
04351P101
Address
Tuborg Boulevard 12
Phone
45 70 22 22 44
Country
DK
Employee
879
IPO Date
Jan 28, 2015
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ASND Financial Summary
CIK
0001612042
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
04351P101
ISIN
US04351P1012
Country
DK
Price
136.38
Beta
0.65
Volume Avg.
453.6k
Market Cap
8.15B
Shares
-
52-Week
111.09-161.0
DCF
-80.97
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-17.44
P/B
-
Website
https://ascendispharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ASND News
It looks like there's no news available.
